NCT04255433
SURMOUNT — tirzepatide in obesity
Phase Phase 3
Status Completed
Indication Obesity
Enrollment 2,539
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT04255433
- Phase
- Phase 3
- Status
- Completed
- Indication
- Obesity
- Primary completion
- 4/1/2022
- Enrollment (planned/actual)
- 2,539
- Sponsor
- Eli Lilly
- Peptide
- Tirzepatide
Peptide under study
Tirzepatide
Dual GIP / GLP-1 receptor agonist · Approved